EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Prudence A Francis iD, Gini F Fleming iD, István Láng, Eva M Ciruelos iD, Hervé R Bonnefoi iD, Meritxell Bellet iD, Antonio Bernardo, Miguel A Climent, Silvana Martino, Begoña Bermejo iD, Harold J Burstein iD, Nancy E Davidson und 16 weitere

Journal of Clinical Oncology · 01.03.2023 · 41 (7) · 1370-1375

DOI: 10.1200/jco.22.01065 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2023. Verfasst von Prudence A Francis und 27 weiteren Autor:innen. Beteiligte Einrichtung: Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690 ) randomly assigned premenopausal women with hormone receptor–positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS versus tamoxifen was a secondary objective. After 8 years, SOFT reported a significant reduction in recurrence and improved overall survival (OS) with adjuvant tamoxifen plus OFS versus tamoxifen alone. Here, we report outcomes after median follow-up of 12 years. DFS remained significantly improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.82; 95% CI, 0.69 to 0.98) with a 12-year DFS of 71.9% with tamoxifen, 76.1% with tamoxifen plus OFS, and 79.0% with exemestane plus OFS. OS was improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.78; 95% CI, 0.60 to 1.01) and was 86.8% with tamoxifen, 89.0% with tamoxifen plus OFS, and 89.4% with exemestane plus OFS at 12 years. Among those who received prior chemotherapy for human epidermal growth factor receptor-2–negative tumors, OS was 78.8% with tamoxifen, 81.1% with tamoxifen plus OFS, and 84.4% with exemestane plus OFS. In conclusion, after 12 years, there remains a benefit from including OFS in adjuvant endocrine therapy, with an absolute improvement in OS more apparent with higher baseline risk of recurrence. [Media: see text]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansAntineoplastic Agents, HormonalChemotherapy, AdjuvantTamoxifenCombined Modality TherapyDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsAdjuvants, ImmunologicPremenopause

Substanzen

Antineoplastic Agents, HormonalTamoxifenAdjuvants, Immunologic

Autor:innen und Institutionen

  • Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.
  • Breast Cancer Trials Australia & New Zealand, University of Newcastle, Callaghan, Newcastle, Australia.
  • International Breast Cancer Study Group, Bern, Switzerland.
  • The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL.
  • Clinexpert-Research, Budapest, Hungary.
  • National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.

ORCID-Profile: Prudence A Francis, Gini F Fleming, Eva M Ciruelos, Hervé R Bonnefoi, Meritxell Bellet, Begoña Bermejo, Harold J Burstein, Barbara A Walley, James N Ingle, Robert E Coleman, Bettina Müller, Fanny Le Du, Sibylle Loibl, Eric P Winer, Sherene Loi, Marco Colleoni, Alan S Coates, Richard D Gelber, Meredith M Regan

Förderung

  • NCI NIH HHS
  • Cancer Research UK

Zitieren

APA

Francis, P. A., Fleming, G. F., Láng, I., Ciruelos, E. M., Bonnefoi, H. R., Bellet, M., Bernardo, A., Climent, M. A., Martino, S., Bermejo, B., Burstein, H. J., Davidson, N. E., Geyer, C. E., Walley, B. A., Ingle, J. N., Coleman, R. E., Müller, B., Le Du, F., Loibl, S., …, & SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation) (2023). Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology, 41(7), 1370-1375. https://doi.org/10.1200/jco.22.01065

Vancouver

Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, et al. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology. 2023;41(7):1370-1375. doi:10.1200/jco.22.01065

BibTeX
@article{Francis2023,
  author = {Francis, Prudence A and Fleming, Gini F and Láng, István and Ciruelos, Eva M and Bonnefoi, Hervé R and Bellet, Meritxell and Bernardo, Antonio and Climent, Miguel A and Martino, Silvana and Bermejo, Begoña and Burstein, Harold J and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Ingle, James N and Coleman, Robert E and Müller, Bettina and Le Du, Fanny and Loibl, Sibylle and Winer, Eric P and Ruepp, Barbara and Loi, Sherene and Colleoni, Marco and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Regan, Meredith M and SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation), SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)},
  title = {Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {7},
  pages = {1370--1375},
  doi = {10.1200/jco.22.01065}
}
Kostenlos starten →